Comparison of immune responses in inbred lines of chickens toEimeria maximaandEimeria tenella

Parasitology ◽  
1995 ◽  
Vol 111 (2) ◽  
pp. 143-151 ◽  
Author(s):  
J. M. Bumstead ◽  
N. Bumstead ◽  
L. Rothwell ◽  
F. M. Tomley

SUMMARYImmune responses of 4 inbred lines of chickens, that differ in resistance toEimeria maximaandE. tenella, were examined. Significant differences were found inin vitroproliferation of peripheral blood lymphocytes toE. maximasporozoite antigen, the more resistant lines C and 72having higher responses than the more susceptible line 151. These differences existed pre-infection and were enhanced following both primary and a second infection. The proportions of lymphocyte subsets in the peripheral blood following primary infection also differed between lines, with significantly higher percentages of CD8 + and TCR1 + lymphocytes circulating in the more resistant birds. In contrast, there were few differences between lines in either resistance or inin vitroproliferation of peripheral blood lymphocytes toE. tenellasporozoite antigen either pre-infection or following a primary infection. However, after a second infection when there were significant differences in resistance between lines, as measured by oocyst excretion, there were also significant differences in lymphoproliferation with the more resistant lines 151 and 62having higher responses than the more susceptible line C. Thus forE. maximathere is a direct relationship between resistance to infection and lymphoproliferation in response to parasite antigen. This implies that differences in cellular immunity may account for differences in resistance between lines, and since these specific responses are enhanced by infection they may also reflect important immune mechanisms. For the rather less immunogenicE. tenella, the correlation between resistance and lymphoproliferation is not so clear. However, where there were significant differences between lines, i.e. after a second infection, the direct relationship between resistance and lymphoproliferation was upheld.

Neurosurgery ◽  
1991 ◽  
Vol 28 (1) ◽  
pp. 16-23 ◽  
Author(s):  
Kevin O. Lillehei ◽  
Dawn H. Mitchell ◽  
Stephen D. Johnson ◽  
Larry E. McCleary ◽  
Carol A. Kruse

Abstract Between August 1986 and October 1987, the Denver Brain Tumor Research Group conducted a clinical trial using autologous human recombinant interleukin-2 (rIL-2)-activated lymphocytes to treat 20 patients with recurrent high-grade gliomas. The trial involved surgical resection and/or decompression followed by intracavitary implantation of lymphokine-activated killer (LAK) cells and autologous stimulated lymphocytes (ASL) along with rIL-2 in a plasma clot. One month later, stimulated lymphocytes and rIL-2 were infused through a Rickham reservoir attached to a catheter directed into the tumor bed. The LAK cells were rIL-2-activated peripheral blood lymphocytes cultured for 4 days; the ASL were lectin- and rIL-2-activated peripheral blood lymphocytes cultured for 10 days. Of the 20 patients treated, 11 were evaluated as a group (mean age, 44 years, range, 15-61 years; mean Karnofsky rating, 69, range, 50-100; mean Decadron dose at entry, 14 mg/d. range, 0-32). The average number of lymphocytes implanted was 7.6 × 109 (range, 1.9-27.5 × 109), together with 1 to 4 × 106 U of rIL-2. To date, 10 of the 11 patients died, all from recurrent tumor growth. The median overall survival time was 63 weeks (range, 36-201; mean, 86). The median survival time after immunotherapy was 18 weeks (range, 11-151; mean, 39). No significant difference in survival after immunotherapy was found between those patients who had received previous chemotherapy and those who had not. The use of steroids or prior chemotherapy did not influence the in vitro generation of ASL or LAK cells. Prior chemotherapy did correlate, however, with diminished in vitro cytotoxicity against the natural killer-sensitive (K562) target cell by LAK cells (P < 0.05) but not that by ASL. There were no major adverse side effects. Although adoptive immunotherapy was safe and well tolerated, its therapeutic potential remains in question.


2017 ◽  
Vol 69 (4) ◽  
pp. 579-589 ◽  
Author(s):  
M. Topaktas ◽  
N. E. Kafkas ◽  
S. Sadighazadi ◽  
E. S. Istifli

Sign in / Sign up

Export Citation Format

Share Document